Therapeutic Asset Ratings
6,538 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
TRASTUZUMAB
Recurrent Bladder Cancer
NKGen Biotech, Inc.
P2
BB
(70)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Breast Cancer
SWOG Cancer Research Network
P4
BB
(69)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.
P4
BB
(69)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Recurrent Childhood Acute Lymphoblastic Leukemia
Peking Union Medical College Hospital
P4
BB
(69)
Ipilimumab
Melanoma
M.D. Anderson Cancer Center
P4
BB
(69)
Ipilimumab
Metastatic Kidney Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
P4
BB
(69)
Nivolumab
Lung Cancer
University of Chicago
P4
BB
(69)
Nivolumab
Melanoma
Bristol-Myers Squibb
P4
BB
(69)
Nivolumab
Non Small Cell Lung Cancer
Fred Hutchinson Cancer Center
P4
BB
(69)
Nivolumab
Renal Cell Carcinoma
Fred Hutchinson Cancer Center
P4
BB
(69)
Pembrolizumab
Melanoma
Biocon Biologics UK PLC
P4
BB
(69)
Pembrolizumab
Metastatic Kidney Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
P4
BB
(69)
Tislelizumab
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P4
BB
(69)
Cetuximab
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Fujian Cancer Hospital
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colon Cancer Stage III
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center
P3
BB
(69)
Ipilimumab
Clinical Stage III Cutaneous Melanoma AJCC v8
Amsterdam UMC, location VUmc
P3
BB
(69)
Ipilimumab
Clinical Stage IV Cutaneous Melanoma AJCC v8
Amsterdam UMC, location VUmc
P3
BB
(69)
Obinutuzumab
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
P3
BB
(69)
Pembrolizumab
Esophageal Carcinoma
NuCana plc
P3
BB
(69)
Tislelizumab
Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
P3
BB
(69)
Alcestobart
NSCLC for Phase 2 Dose Expansion
BeiGene
P2
BB
(69)
Atezolizumab
HER2 Negative
TransThera Sciences (Nanjing), Inc.
P2
BB
(69)
Cetuximab
Rectal Cancer
Tang-Du Hospital
P2
BB
(69)
Showing 101 to 125 of 6,538 assets
Previous
Page 5 of 262
Next